AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29533729 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant survival rates
Number of subjects: 96
Study 29533729 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and lower jaws
Number of subjects: 96
Study 28348503 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 28348503 — intervention group
Group type: COMPARATOR
Intervention: Control (Regional anesthesia with opioid PCA)
Number of subjects: 0
Study 26222435 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone vaginal progesterone gel (90 mg/d)
Number of subjects: 1500
Study 26222435 — intervention group
Group type: COMPARATOR
Intervention: Intramuscularly injected progesterone (40 mg/d)
Number of subjects: 1500
Study 23743437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% preservative-free ophthalmic solution
Number of subjects: 597
Study 23743437 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost 0.03% ophthalmic solution (Lumigan)
Number of subjects: 597
Study 20639714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (40 mg/kg/day for 3 months)
Number of subjects: 120
Study 20639714 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments for FTT (Control)
Number of subjects: 120
Study 18191048 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 34
Study 18191048 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 17722305 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivir (test formulation)
Number of subjects: 28
Study 17722305 — intervention group
Group type: COMPARATOR
Intervention: Retrovir (reference formulation)
Number of subjects: 28
Study 14508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping others
Number of subjects: 2016
Study 14508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving help
Number of subjects: 2016
Study 14508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling overwhelmed by others' demands
Number of subjects: 2016
Study 14508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer activities, satisfaction with prayer life, positive religious coping, age, female gender, being a church elder
Number of subjects: 2016
Study 14508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of prayer and negative religious coping
Number of subjects: 2016
Study 14508020 — intervention group
Group type: EXPERIMENTAL
Intervention: General health, positive and negative religious coping, asking God for healing
Number of subjects: 2016
Study 11106311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.0 mg)
Number of subjects: 60
Study 11106311 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.0 mg)
Number of subjects: 60
Study 11106311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9183041 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 356
Study 9183041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 8237806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated magnesium chloride (15.8 mmol magnesium per day)
Number of subjects: 21
Study 3752618 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized aluminum hydroxide‐bound dog dander and hair extract
Number of subjects: 27
Study 3752618 — intervention group
Group type: COMPARATOR
Intervention: Histamine-placebo
Number of subjects: 27
Study 30243812 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered, low literacy intervention promoting diabetes self-care including the ACP Diabetes Guide, brief counseling strategy, and training module for health coaches.
Number of subjects: 0
Study 27127913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 20
Study 24268595 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention in a specialised outpatient mood disorder clinic
Number of subjects: 158
Study 24268595 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 158
Study 23253957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 512
Study 23253957 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Number of subjects: 512
Study 23253957 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter
Number of subjects: 512
Study 23253957 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 512
Study 20389141 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 100
Study 20389141 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 100
Study 18241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft
Number of subjects: 20
Study 18241756 — intervention group
Group type: COMPARATOR
Intervention: Standard Gore‐Tex Thin Walled Stretch Vascular Graft
Number of subjects: 20
Study 16902573 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational material by post and an academic detailing visit by a trained pharmacist (intervention group)
Number of subjects: 1497
Study 16902573 — intervention group
Group type: COMPARATOR
Intervention: Educational material by post (guideline group)
Number of subjects: 1497
Study 16902573 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1497
Study 14600112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dislike of school
Number of subjects: 0
Study 14600112 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic disadvantage
Number of subjects: 0
Study 14600112 — intervention group
Group type: COMPARATOR
Intervention: Comparable knowledge to those liking school
Number of subjects: 0
Study 10658740 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron beam CT
Number of subjects: 160
Study 10658740 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT with pitch of 2
Number of subjects: 160
Study 10658740 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-slice CT without prospective ECG triggering
Number of subjects: 160
Study 10658740 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-slice CT with prospective ECG triggering
Number of subjects: 160
Study 10658740 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT (all modes)
Number of subjects: 160
Study 8653499 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% polyacrylic acid cleaning for 10-15 seconds
Number of subjects: 137
Study 8653499 — intervention group
Group type: COMPARATOR
Intervention: Water rinsing with copious amounts of water
Number of subjects: 137
Study 1621794 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises; Duration: 6 weeks; Self-help program
Number of subjects: 10
Study 6336824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (pure oxygen)
Number of subjects: 40
Study 6336824 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (10% oxygen and 90% nitrogen)
Number of subjects: 40
Study 30887581 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 36
Study 29571842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3288
Study 29571842 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3288
Study 25404752 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous endurance training (n=20): 33 min at 65-85% peak heart rate
Number of subjects: 60
Study 25404752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (n=20): 4 × 4 min intervals at 85-95% peak heart rate, followed by 3 min of active recovery at 60-70% peak heart rate
Number of subjects: 60
Study 25404752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramid training (n=20): 3 × 8 min of stepwise load increase and decrease from 65-95-65% peak heart rate, with 2 min recovery at 60-70% peak heart rate
Number of subjects: 60
Study 24651814 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of leptomeningeal collaterals
Number of subjects: 39
Study 24651814 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation of the anterior choroidal artery
Number of subjects: 39
Study 24651814 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior communicating artery/ICA ratio
Number of subjects: 39
Study 24651814 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of infarct or hemorrhage
Number of subjects: 39
Study 24651814 — intervention group
Group type: COMPARATOR
Intervention: Posterior communicating artery/ICA ratio and leptomeningeal collaterals
Number of subjects: 39
Study 23115621 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (Gardasil™) - Dose 1
Number of subjects: 404
Study 20956076 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered FSWs
Number of subjects: 187
Study 20956076 — intervention group
Group type: COMPARATOR
Intervention: Unregistered FSWs
Number of subjects: 187
Study 17388666 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated peer education, free condom distribution, and syndromic STI management
Number of subjects: 0
Study 17388666 — intervention group
Group type: EXPERIMENTAL
Intervention: Males attending program meetings
Number of subjects: 0
Study 17388666 — intervention group
Group type: EXPERIMENTAL
Intervention: Male STI patients in intervention communities
Number of subjects: 0
Study 17388666 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 0
Study 15381923 — intervention group
Group type: EXPERIMENTAL
Intervention: RGS4 polymorphisms in first episode schizophrenia patients
Number of subjects: 57
Study 15381923 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without RGS4 polymorphisms
Number of subjects: 57
Study 12160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg once daily
Number of subjects: 409
Study 12160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg once daily
Number of subjects: 409
Study 12160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 400 mg once daily
Number of subjects: 409
Study 12160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg twice daily
Number of subjects: 409
Study 12160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg twice daily
Number of subjects: 409
Study 12160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 200 mg twice daily
Number of subjects: 409
Study 12160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg twice daily
Number of subjects: 409
Study 12160194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 10466981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (ivermectin and albendazole)
Number of subjects: 0
Study 10466981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10466981 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 0
Study 10466981 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 0
Study 7838545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive applied to one side of the nasal cavity
Number of subjects: 12
Study 7838545 — intervention group
Group type: COMPARATOR
Intervention: Control side with packing coated with bacitracin
Number of subjects: 12
Study 2090474 — intervention group
Group type: COMPARATOR
Intervention: Maintenance Dose (MD)
Number of subjects: 32
Study 2090474 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice the Maintenance Dose (MDx2)
Number of subjects: 32
Study 6444958 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% erythromycin
Number of subjects: 348
Study 6444958 — intervention group
Group type: COMPARATOR
Intervention: vehicle (alcohol/propylene glycol)
Number of subjects: 348
Study 31165191 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg every 4 weeks
Number of subjects: 134
Study 31165191 — intervention group
Group type: COMPARATOR
Intervention: Burosumab after placebo
Number of subjects: 134
Study 31165191 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 134
Study 26198645 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid BPD with MST-related PTSD
Number of subjects: 90
Study 26198645 — intervention group
Group type: COMPARATOR
Intervention: Veterans without comorbid BPD
Number of subjects: 90
Study 25790233 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rectal indomethacin
Number of subjects: 539
Study 25790233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 23554113 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 5 days
Number of subjects: 374
Study 23554113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 21134775 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (IV or oral)
Number of subjects: 1056
Study 21134775 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (IV)
Number of subjects: 1056
Study 19136101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 injection of bupivacaine and triamcinolone
Number of subjects: 50
Study 19136101 — intervention group
Group type: COMPARATOR
Intervention: 2 injections of bupivacaine and triamcinolone
Number of subjects: 50
Study 18978166 — intervention group
Group type: EXPERIMENTAL
Intervention: Muesli with 4 g oat beta-glucan
Number of subjects: 12
Study 18978166 — intervention group
Group type: COMPARATOR
Intervention: Cornflakes meal
Number of subjects: 12
Study 16291063 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 162
Study 16291063 — intervention group
Group type: COMPARATOR
Intervention: Standard moist wound care
Number of subjects: 162
Study 12016603 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (2.5% lidocaine and 2.5% prilocaine)
Number of subjects: 300
Study 12016603 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine (4% AMET)
Number of subjects: 300
Study 12016603 — intervention group
Group type: EXPERIMENTAL
Intervention: AMLI (2.5% amethocaine and 2.5% lidocaine)
Number of subjects: 300
Study 10465130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime monotherapy
Number of subjects: 69
Study 10465130 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with trimethoprim/sulfamethoxazole plus amikacin (TMP/SMZ plus AMI)
Number of subjects: 69
Study 8556967 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 113
Study 8556967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 8556967 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (nasal users)
Number of subjects: 113
Study 8556967 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal users)
Number of subjects: 113
Study 8556967 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (depressed users)
Number of subjects: 113
Study 8556967 — intervention group
Group type: COMPARATOR
Intervention: Placebo (depressed users)
Number of subjects: 113
Study 1697490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day for 4 weeks
Number of subjects: 60
Study 1697490 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 1 g/day for 4 weeks
Number of subjects: 60
Study 1107506 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/m2 of synthetic luteinizing hormone‐releasing hormone
Number of subjects: 20
Study 31711990 — intervention group
Group type: COMPARATOR
Intervention: Active aspiration
Number of subjects: 142
Study 31711990 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity drainage
Number of subjects: 142
Study 29056595 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured, prefabricated foot orthoses (n=153)
Number of subjects: 306
Study 29056595 — intervention group
Group type: COMPARATOR
Intervention: Flat insoles (control group, n=153)
Number of subjects: 306
Study 28401667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (3.5-4 hours in bed per night)
Number of subjects: 43
Study 28401667 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (7-9 hours in bed per night)
Number of subjects: 43
Study 26167716 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (2.7-3.0% THC)
Number of subjects: 89
Study 26167716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 23923440 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam (PU) applied in one extraction socket
Number of subjects: 10
Study 23923440 — intervention group
Group type: COMPARATOR
Intervention: Commercially available gelatin foam applied in the other socket (gelatin group)
Number of subjects: 10
Study 23923440 — intervention group
Group type: COMPARATOR
Intervention: Collagen wadding applied in the other socket (collagen group)
Number of subjects: 10
Study 21515226 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lumiracoxib
Number of subjects: 51
Study 21515226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 21515226 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 51
Study 18070204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 6% active complex antiageing cream
Number of subjects: 9
Study 18070204 — intervention group
Group type: COMPARATOR
Intervention: Topical application of all-trans retinoic acid (RA)
Number of subjects: 9
Study 18070204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 2% active complex antiageing cream
Number of subjects: 9
Study 18070204 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of basic moisturizer
Number of subjects: 9
Study 16801738 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus lifestyle management (OLM)
Number of subjects: 107
Study 16801738 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 107
Study 12657858 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg parecoxib sodium
Number of subjects: 0
Study 12657858 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib sodium
Number of subjects: 0
Study 12657858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11043842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium clodronate 1600 mg daily p.o. (arm A)
Number of subjects: 73
Study 11043842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm B)
Number of subjects: 73
Study 8842890 — intervention group
Group type: EXPERIMENTAL
Intervention: Community organization strategies including local physician planning groups, informational mailings, medical office staff training sessions, and reminder system support.
Number of subjects: 0
Study 8842890 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no specific intervention mentioned).
Number of subjects: 0
Study 1735269 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen (Ag) inhalation
Number of subjects: 10
Study 6733511 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform radiant heat stimuli of 18 s duration, raising skin surface temperature by 6 degrees C to a painful level (41‐43 degrees C) at interstimulus intervals of 35 s, 70 s, and 105 s.
Number of subjects: 7
Study 30915650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab
Number of subjects: 132
Study 30915650 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abatacept
Number of subjects: 132
Study 29590118 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional BMI change in Q1 (<-2.1 kg/m2)
Number of subjects: 321
Study 29590118 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional BMI change in Q2 (-2.1 to -0.9 kg/m2)
Number of subjects: 321
Study 29590118 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional BMI change in Q3 (-0.9 to 0.1 kg/m2)
Number of subjects: 321
Study 29590118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Q1 to Q3
Number of subjects: 321
Study 29590118 — intervention group
Group type: COMPARATOR
Intervention: Control group (Q4, gained ≥0.1 kg/m2)
Number of subjects: 321
Study 26675766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis in randomized controlled trials
Number of subjects: 0
Study 26675766 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed 8-step strategy for conducting sensitivity analyses
Number of subjects: 0
Study 24531843 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimmer's position (SWIM)
Number of subjects: 380
Study 24531843 — intervention group
Group type: COMPARATOR
Intervention: Standard position (STD)
Number of subjects: 380
Study 19202154 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine invasive strategy
Number of subjects: 184
Study 19202154 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 184
Study 19202154 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (meta-analysis)
Number of subjects: 184
Study 20391869 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonviolence training
Number of subjects: 58
Study 20391869 — intervention group
Group type: COMPARATOR
Intervention: Untrained comparison group
Number of subjects: 58
Study 20391869 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonviolence instruction
Number of subjects: 58
Study 18622283 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced TAC (target trough level 3.0‐5.9 ng/mL)
Number of subjects: 0
Study 18622283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard TAC (target trough level 6.0‐8.9 ng/mL)
Number of subjects: 0
Study 18622283 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and low-density lipoprotein cholesterol in both TAC groups
Number of subjects: 0
Study 18622283 — intervention group
Group type: COMPARATOR
Intervention: All TAC groups
Number of subjects: 0
Study 18622283 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-treated patients
Number of subjects: 0
Study 16324598 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (2 months, resistive load of 40% of PImax)
Number of subjects: 35
Study 16324598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 35
Study 11833837 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix75/25
Number of subjects: 143